Deciphera Pharmaceuticals (DCPH) Raised to Strong-Buy at BidaskClub

BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a strong-buy rating in a research report released on Saturday.

DCPH has been the topic of a number of other reports. JPMorgan Chase & Co. started coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an overweight rating and a $30.00 price objective on the stock. Instinet started coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. JMP Securities started coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an outperform rating and a $38.00 price objective on the stock. Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, January 15th. Finally, Nomura started coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $40.83.

Deciphera Pharmaceuticals (NASDAQ:DCPH) opened at $27.94 on Friday. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $28.96.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($5.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30). analysts forecast that Deciphera Pharmaceuticals will post -2.91 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of DCPH. American International Group Inc. purchased a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter worth $126,000. SG Americas Securities LLC purchased a new stake in shares of Deciphera Pharmaceuticals during the 3rd quarter worth $143,000. FNY Managed Accounts LLC purchased a new stake in shares of Deciphera Pharmaceuticals during the 3rd quarter worth $153,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter worth $179,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter worth $288,000. Institutional investors own 44.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Deciphera Pharmaceuticals (DCPH) Raised to Strong-Buy at BidaskClub” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/deciphera-pharmaceuticals-dcph-raised-to-strong-buy-at-bidaskclub.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply